Miimansa
Miimansa AI is an Indian health-tech company that builds AI-powered software to transform unstructured clinical data into standardized, OMOP-compliant datasets for hospitals, CROs, and pharma via its BridgeCloud platform.
- Company typePrivate
- Founded2023
- Headquarters—
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Miimansa does
Miimansa AI is an Indian health-tech company that builds AI-powered software for transforming unstructured clinical data into standardized, analytics-ready datasets. The company's flagship platform, BridgeCloud™, operates as a four-stage pipeline: PrivacyBridgeAI handles locale-aware PHI de-identification; MedBridgeAI structures and normalizes clinical texts into OMOP/CDM, FHIR, and SNOMED-compliant datasets; KnowledgeBridgeAI delivers real-time evidence retrieval and conversational AI over clinical literature; and TrialBridgeAI (in development) supports patient cohort discovery and clinical trial feasibility. The platform is powered by a patent-pending proprietary retrieval framework called AIPR (Anchor-Indexed Passage Retrieval), which combines domain-adapted embeddings, key-phrase indexing, and hierarchical semantic search for clinical text. Miimansa also offers a MedBridgeAI Copilot add-on to accelerate OMOP CDM 5.4 transformation workflows.
The company primarily serves enterprise healthcare and life sciences buyers, including hospitals, academic medical centers, clinical research organizations (CROs), pharmaceutical companies, and insurance firms. Its go-to-market is enterprise sales-led with a 'Request a Demo' conversion model, supplemented by strategic channel partnerships — most notably a multi-year partnership with Emmes Group for global CRO distribution. Revenue is generated through SaaS subscriptions and managed services, though pricing is quote-based and not publicly disclosed. Miimansa's defensibility rests on locale-specific AI models tuned for Indian clinical data, research collaborations with IIT Kanpur, SGPGIMS, and ICMR-NIRDHDS, and a leadership team with Stanford and IIT credentials. The company has 1-10 employees, is privately held, and has not disclosed any institutional funding rounds.
Miimansa firmographics
Firmographics- Name
- Miimansa
- Legal name
- Miimansa AI
- Website
- https://miimansa.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Miimansa AI is an Indian health-tech company that builds AI-powered software to transform unstructured clinical data into standardized, OMOP-compliant datasets for hospitals, CROs, and pharma via its BridgeCloud platform.
- Ownership category
- akta.pro rank
Miimansa industry classification
Industry- Product category
- Healthcare AI Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Terminology Services & Semantic Interoperability (SNOMED/LOINC/RxNorm mapping) (HLACABAJ)
- akta.pro secondary industries
- DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO), Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)
Keywords
Miimansa business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- MedBridgeAI SaaS Subscription: Cloud-native, privacy-safe AI delivered as a service for OMOP CDM transformation. Customers avoid infrastructure build-out while maintaining strong data governance. Operates on subscription basis with zero compute-hardware investment required from clients.
- BridgeCloud™ Platform Services: Integrated platform providing end-to-end de-identification pipeline, standardization, and AI-driven clinical data transformation as managed services. Includes automated compliance reports, interactive dashboards, and API access.
- TrialBridgeAI (Under Development): Patient matching and cohort discovery capabilities currently under development with clinical research partners for joint pilot studies.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
Miimansa product offering
Product offeringCore offering
Miimansa develops and sells BridgeCloud, an AI-powered clinical data transformation platform that ingests unstructured patient notes from electronic health records (EHRs) and converts them into structured, de-identified, standardized datasets ready for research, analytics, and clinical trials. The platform bundles privacy-preserving de-identification, clinical NLP coding to ICD-10/SNOMED/RxNorm/LOINC, knowledge graph construction, and a conversational AI copilot, sold to healthcare providers, CROs, pharmaceutical/life sciences companies, and insurance payers.
Product overview
Miimansa offers BridgeCloud™, an integrated AI-powered cloud platform for clinical data transformation. The platform comprises four modular products that work together in a pipeline architecture: PrivacyBridgeAI (Stage 1 - Privacy/De-identification) securely de-identifies raw clinical records with locale-aware precision; MedBridgeAI (Stage 2 - Structure) transforms safe data into OMOP/CDM-normalized structured datasets; KnowledgeBridgeAI (Stage 3 - Insight) mines structured data for real-time knowledge retrieval and conversational AI; and TrialBridgeAI (Stage 4 - Action) enables intelligent patient matching and cohort discovery for clinical research. An optional MedBridgeAI Copilot add-on accelerates OMOP CDM 5.4 transformation workflows. The platform is powered by proprietary patent-pending AIPR (Anchor-Indexed Passage Retrieval) technology for semantic search and retrieval-augmented generation.
Differentiator
Problem solved
Functional benefit
Products and services
- BridgeCloud Platform
Quantifiable outcome
- 60-70% reduction in clinical data curation time
- +11 more outcomes
Companies that use Miimansa
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Miimansa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature8 records
Miimansa partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and strategic.
- Emmes GroupflagshipMulti-year strategic partnership with Emmes Group, a leading specialty tech-enabled global CRO with over 45 years of experience. Joint development of advanced clinical data management solutions, integration of AI technologies into clinical trial workflows, and AI-powered clinical document authoring. The 'Innovation-to-Impact' model positions Miimansa as the innovation engine and Emmes as the impact driver.
- IIT Kanpur (Indian Institute of Technology Kanpur)coreResearch collaboration focused on advanced AI and machine learning technologies for healthcare applications. Joint research on PHI de-identification systems, natural language processing for clinical text, AI model development and validation, and Digital Public Goods for AI in Health.
- SGPGIMS (Sanjay Gandhi Postgraduate Institute of Medical Sciences)coreCollaboration with SGPGIMS for clinical validation and real-world testing of AI systems. Joint work on AI-powered clinical data de-identification and data warehousing, participation in AI committee, and real-world validation of MedBridgeAI implementation in the Nephrology department.
- ICMR-NIRDHDS (Indian Council of Medical Research - National Institute for Research in Digital Health and Data Science)strategicPartnership on healthcare standards and ethical frameworks. Joint initiatives include ethical AI framework collaboration, ethics committee participation, and research methodology best practices for responsible AI in healthcare.
Scale indicators3 records
Recent moves6 records
Expansion highlights7 records
Miimansa competitors and assessment
Company assessmentDirect peers
- Deep 6 AI: AI-powered patient matching and cohort discovery platform for clinical trials. Directly comparable to Miimansa's TrialBridgeAI in translating eligibility criteria against EHR data to accelerate trial recruitment.
- John Snow Labs: Healthcare-focused NLP company offering Spark NLP for clinical and biomedical text, including de-identification, entity extraction, and terminology mapping. Closest comparable in clinical text transformation with an established customer base across pharma and providers.
- Flatiron Health: Oncology-focused clinical data platform (acquired by Roche) that structures EHR data for real-world evidence and research. Directly comparable to MedBridgeAI's oncology use cases and OMOP-based clinical data transformation.
- TriNetX: Global health research network leveraging real-world data and clinical trial analytics. Comparable to MedBridgeAI/KnowledgeBridgeAI in enabling federated queries across standardized clinical datasets for pharma-sponsored research.
- Datavant: Healthcare data connectivity company specializing in privacy-preserving record linkage and de-identification of patient data. Highly comparable to Miimansa's PrivacyBridgeAI and data exchange functionality across the clinical research value chain.
Broad incumbents
- AWS Comprehend Medical: Amazon's cloud-based clinical NLP service for entity extraction, de-identification, and medical text analysis. Hyperscaler incumbent that competes at the baseline feature set of Miimansa's PrivacyBridgeAI and MedBridgeAI.
- IQVIA: Largest global CRO and real-world evidence provider offering comprehensive clinical research, data, and technology services. Comparable as a customer/competitor in the CRO + clinical data analytics space Miimansa targets through Emmes partnership.
- Google Cloud Healthcare API: Google's healthcare data platform supporting FHIR, DICOM, and HL7v2 interoperability. Comparable to Miimansa's FHIR/SNOMED integration capabilities but as part of a much broader cloud ecosystem rather than a focused clinical AI stack.
- Microsoft Cloud for Healthcare: Microsoft's healthcare-focused cloud offering with FHIR-based data aggregation, AI services, and clinical insights. Broad incumbent comparable to Miimansa's interoperability and AI-driven insights functionality but at hyperscaler scale.
Emerging players
- Mendel AI: Clinical NLP company that transforms unstructured medical records into structured data for healthcare and life sciences use cases. Comparable in clinical text structuring, though with broader US enterprise focus versus Miimansa's Indian specialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Miimansa social profiles
Digital presenceMiimansa compliance and trust
Trust signalCompliance4 records
Miimansa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Miimansa leadership team
Management profileNumber of profiles
Profiles5 records
Miimansa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Miimansa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Miimansa
What does Miimansa do?
Miimansa develops and sells BridgeCloud, an AI-powered clinical data transformation platform that ingests unstructured patient notes from electronic health records (EHRs) and converts them into structured, de-identified, standardized datasets ready for research, analytics, and clinical trials. The platform bundles privacy-preserving de-identification, clinical NLP coding to ICD-10/SNOMED/RxNorm/LOINC, knowledge graph construction, and a conversational AI copilot, sold to healthcare providers, CROs, pharmaceutical/life sciences companies, and insurance payers.
Is Miimansa a public or private company?
Miimansa is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Miimansa founded?
Miimansa was founded in 2023. It employs 1 to 10 people.
How does Miimansa make money?
Three revenue lines are on record. MedBridgeAI SaaS Subscription is the primary driver. The others are bridgeCloud™ Platform Services and trialBridgeAI (Under Development).
Who are Miimansa's main competitors?
Direct peers on record are Deep 6 AI, John Snow Labs, Flatiron Health, TriNetX and Datavant. Broad incumbents are AWS Comprehend Medical, IQVIA, Google Cloud Healthcare API and Microsoft Cloud for Healthcare. Mendel AI is listed as an emerging player.
Does Miimansa have an API?
No public API is recorded for Miimansa.
What industry is Miimansa in?
Miimansa's product category is Healthcare AI Software. Its primary akta.pro industry code is HLACABAJ, Terminology Services & Semantic Interoperability (SNOMED/LOINC/RxNorm mapping), with a secondary code of HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 513210 and its SIC code is 8000.